Report

  1. Home
  2. Healthcare
  3. Medical Equipment
  4. Healthcare IT

Electronic Clinical Outcome Assessment (eCOA) Solution Market by Modality (Wearable, Mobile, BYOD), Type (PRO, CLINRO, OBSRO, PERFO), Use ([Clinical trial: Onco, Rare, Mental Health], RWE, Registery], End User, and Region - Global Forecast to 2029

Market Report I 2024-02-20 I 413 Pages I MarketsandMarkets

The electronic clinical outcome assessment (eCOA) solutions market is projected to reach USD 3.9 billion by 2029 from USD 1.8 billion in 2024, at a CAGR 16.6% during the forecast period. The the growing inclination towards digital data collection and analysis, an escalating need for economical data collection solutions, and the increasing integration of connected devices in healthcare institutions are the factors that will drive the growth of this market. On the other hand, the sensitivity of patient health data requires robust security measures. Concerns about data breaches, unauthorized access, or cybersecurity threats may impede the adoption of eCOA solutions to a certain extent over the forecast period.

"The BYOD (bring your own device) model segment is estimated to hold the major share in 2023, by type of wearable, mobile and other devices."
The wearable, mobile and other devices market is bifurcated into BYOD (bring your own device) model, provisioned device model, and hybrid model. The BYOD model segment accounted for the largest market share during the forecast period. The growth of BYOD (Bring Your Own Device) adoption is driven by cost-effectiveness, as it eliminates the need for sponsors to manage dedicated devices, lowering trial costs. Patient familiarity with their own devices enhances user-friendliness, boosting engagement and data quality, while increasing accessibility for geographically dispersed and resource-limited patients, aligning with decentralized trials. Additionally, technological advancements in secure data encryption address security concerns, and evolving regulations favor secure BYOD implementation in certain regions, positioning it as a cost-efficient, patient-centric approach in clinical trials.

"Clinical trials segment is estimated to hold the largest share of electronic clinical outcome assessment (eCOA) solutions market, by application."
Based on application, the Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into clinical trials, observational studies and real-world evidence (RWE) generation, patient management and registries, and other applications. The clinical trials segment is expected to hold the largest share during the forecast period. The rise of eCOA (Electronic Clinical Outcome Assessment) in clinical trials is driven by a myriad of advantages: heightened data quality achieved through real-time capture and minimized transcription errors, enhanced patient engagement facilitated by user-friendly platforms and improved data ownership, and increased trial efficiency through streamlined data collection and accelerated analysis. This results in superior-quality studies, increased patient satisfaction, and expedited drug development, positioning eCOA as the emerging gold standard for a more efficient, patient-centric future in clinical research.

"Electronic Observer-Reported Outcomes (EOBSRO) segment is expected to register highest growth in the forecast period, by product type segment."
Based on product type, the Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into electronic patient-reported outcomes (EPRO), Electronic Clinician-reported outcomes (ECLINRO), electronic observer-reported outcomes (EOBSRO), and Electronic performance-reported outcomes (EPERFO). In 2023, the electronic observer-reported outcomes (EOBSRO) segment segment is expected to register highest growth in the forecast period. Observer-reported outcomes (ObsRO) play a crucial role in gathering real-world evidence outside controlled trial settings, informing post-market research and regulatory decisions. Effective patient monitoring in decentralized trials, improved data quality, availability of holistic picture of patient experience and treatment response are some of the factors that contribute to the growth of the segment.

"Asia Pacific to register the highest growth in the electronic clinical outcome assessment (eCOA) solutions market in the forecast period."
The global electronic clinical outcome assessment (eCOA) solutions market is segmented into four major regions, namely, North America, Europe, APAC, and the Rest of the World. In 2022, Asia Pacific was expected to register the highest growth for electronic clinical outcome assessment (eCOA) solutions systems in the forecast period. Factors such as increasing healthcare expenditure, developing healthcare infrastructure, rising demand for digital solutions in healthcare sector, large patient population, increasing focus on patient-centric care and the need for better data collection and analysis are expected to drive the growth of the electronic clinical outcome assessment (eCOA) solutions market in the Asia Pacific.

Breakdown of the supply-side, demand side, primary interviews by company type, designation, and region:
- By Supply Side: Tier 1 (31%), Tier 2 (28%), and Tier 3 (41%)
- By Demand Side: Hospital Directors/VPs/Managers/Department Heads (40%), Pharma & Biopharma Company's Product managers, Purchase Heads, etc. (35%), and Others (25%).
- By Designation: C-level Executives (31%), Director-level (25%), and Managers (44%)
- By Region: North America (45%), Europe (20%), Asia Pacific (28%), and RoW (4%)

The prominent players in this market are Koninklijke Signant Health (US), IQVIA Holdings, Inc. (US), Oracle (US), Clario (US), Medable Inc. (US), Medidata (US), Merative (US), ICON plc (Ireland), Paraxel International (MA) Corporation (US), Climedo Health GmbH (Germany), Healthentia (Belgium), Veeva Systems (US), assisTek (US), Curebase Inc. (US), Castor (US), EvidentIQ Group GmbH (Germany), YPrime, LLC. (US), Clinical ink (US), Clinion (US), Kayentis (France), TransPerfect (US), ObvioHealth USA, Inc. (US), WCG Clinical (Germany), ClinCapture (US), and Cloudbyz (US). Players adopted organic as well as inorganic growth strategies such as product launches and enhancements, and investments, partnerships, collaborations, joint ventures, funding, acquisition, expansions, agreements, sales contracts, and alliances to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Research Coverage
- The report studies the electronic clinical outcome assessment (eCOA) solutions market based on component, product type, deployment model, application area, end user, and region.
- The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
- The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
- The report studies micro-markets with respect to their growth trends, prospects, and contributions to the total electronic clinical outcome assessment (eCOA) solutions market.
- The report forecasts the revenue of market segments with respect to five major regions.

Reasons to Buy the Report
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:
- Analysis of key drivers (increasing R&D expenditure for product development by medtech, and pharma-biotech companies, rising operational costs and regulatory requirements associated with clinical research studies, favorable government support and funding for clinical trials, growing prevalence of chronic diseases & subsequent increase in clinical trials, effective monitoring of clinical data, reduction in overall costs and timelines of clinical trials), restraints (lack of skilled professionals to develop and operate eCOA solutions, high implementation and maintenance cost, lack of awareness about eCOA solutions among end users), opportunities (surging eCOA adoption owing to increasing number of clinical trials in emerging economies, growing outsourcing of clinical trial processes to CROs, gradual shift from manual data interpretation to real-time data analysis, growing penetration of mobile technology in healthcare industry), and challenges (evolving regulatory landscape and compliance requirements, interoperability & integration, data security & privacy issues, resistance from traditional healthcare professionals and concerns regarding software reliability) influencing the growth of electronic clinical outcome assessment (eCOA) solutions market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the electronic clinical outcome assessment (eCOA) solutions market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of electronic clinical outcome assessment (eCOA) solutions solutions across regions.
- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the electronic clinical outcome assessment (eCOA) solutions market.
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the electronic clinical outcome assessment (eCOA) solutions market.

1 INTRODUCTION 58
1.1 STUDY OBJECTIVES 58
1.2 MARKET DEFINITION 58
1.2.1 INCLUSIONS & EXCLUSIONS 59
1.3 MARKET SCOPE 60
1.3.1 MARKET SEGMENTATION 60
FIGURE 1 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET SEGMENTATION 60
1.3.2 REGIONAL SCOPE 61
1.4 YEARS CONSIDERED 61
1.4.1 CURRENCY CONSIDERED 62
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 62
1.5 STAKEHOLDERS 62
1.6 RECESSION IMPACT 62
2 RESEARCH METHODOLOGY 63
2.1 RESEARCH DATA 63
FIGURE 2 RESEARCH DESIGN 63
2.2 SECONDARY SOURCES 64
2.2.1 KEY DATA FROM SECONDARY SOURCES 65
2.3 PRIMARY DATA 65
2.3.1 PRIMARY SOURCES 66
2.3.1.1 Key data from primary sources 67
2.3.1.2 Key industry insights 68
2.3.2 BREAKDOWN OF PRIMARY INTERVIEWS 68
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY CATEGORY, DESIGNATION, AND REGION 68
2.4 RESEARCH METHODOLOGY DESIGN 69
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 69
2.5 MARKET SIZE ESTIMATION 69
FIGURE 5 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS 70
2.5.1 BOTTOM-UP APPROACH 71
FIGURE 6 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: BOTTOM-UP APPROACH 71
FIGURE 7 DEMAND-SIDE APPROACH: END-USER SPENDING ON ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS 72
2.5.2 TOP-DOWN APPROACH 72
FIGURE 8 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: TOP-DOWN APPROACH 73
TABLE 2 FACTOR ANALYSIS 74
FIGURE 9 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 75
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 76
2.6 MARKET BREAKDOWN & DATA TRIANGULATION 77
FIGURE 11 DATA TRIANGULATION METHODOLOGY 77
2.7 ASSUMPTIONS 78
2.7.1 MARKET SIZING ASSUMPTIONS 78
2.7.2 OVERALL STUDY ASSUMPTIONS 78
2.8 LIMITATIONS 79
2.8.1 SCOPE-RELATED LIMITATIONS 79
2.8.2 METHODOLOGY-RELATED LIMITATIONS 79
2.9 RISK ASSESSMENT 79
TABLE 3 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: RISK ASSESSMENT 79
2.10 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: RECESSION IMPACT ANALYSIS 79
TABLE 4 GLOBAL INFLATION RATE PROJECTIONS, 2021-2028 (% GROWTH) 79
TABLE 5 US HEALTH EXPENDITURE, 2019-2022 (USD MILLION) 80
TABLE 6 US HEALTH EXPENDITURE, 2023-2030 (USD MILLION) 80
3 EXECUTIVE SUMMARY 81
FIGURE 12 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2024 VS. 2029 (USD MILLION) 81
FIGURE 13 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2024 VS. 2029 (USD MILLION) 82
FIGURE 14 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION) 83
FIGURE 15 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2024 VS. 2029 (USD MILLION) 84
FIGURE 16 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION) 84
FIGURE 17 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION) 85
FIGURE 18 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 86
FIGURE 19 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: GEOGRAPHIC SNAPSHOT 87
4 PREMIUM INSIGHTS 88
4.1 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET OVERVIEW 88
FIGURE 20 GOVERNMENT INITIATIVES & SURGING R&D EXPENDITURES TO DRIVE MARKET GROWTH 88
4.2 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT AND COUNTRY (2023) 89
FIGURE 21 JAPAN ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023 89
4.3 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 90
FIGURE 22 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 90
4.4 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: REGIONAL MIX (2021?2029) 91
FIGURE 23 NORTH AMERICA TO CONTINUE TO DOMINATE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET DURING FORECAST PERIOD 91
4.5 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: DEVELOPED VS. EMERGING ECONOMIES 92
FIGURE 24 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 92
5 MARKET OVERVIEW 93
5.1 INTRODUCTION 93
5.2 MARKET DYNAMICS 93
FIGURE 25 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 93
5.2.1 MARKET DYNAMICS: IMPACT ANALYSIS 94
5.2.2 DRIVERS 95
5.2.2.1 Increasing R&D expenditure for product development by medtech and pharma-biotech companies 95
FIGURE 26 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2014-2028 95
5.2.2.2 Rising operational costs and regulatory requirements associated with clinical research studies 96
5.2.2.3 Favorable government support and funding for clinical trials 96
5.2.2.4 Growing prevalence of chronic diseases & subsequent increase in clinical trials 97
5.2.2.5 Effective monitoring of clinical data 98
5.2.2.6 Reduction in overall costs and timelines of clinical trials 98
5.2.3 RESTRAINTS 98
5.2.3.1 Dearth of skilled professionals to develop and operate eCOA solutions 98
5.2.3.2 High implementation and maintenance costs 99
5.2.3.3 Lack of awareness about eCOA solutions among end users 99
5.2.4 OPPORTUNITIES 100
5.2.4.1 Surging eCOA adoption owing to increasing number of clinical trials in emerging economies 100
5.2.4.2 Growing outsourcing of clinical trial processes to CROs 100
5.2.4.3 Gradual shift from manual data interpretation to real-time data analysis 101
5.2.4.4 Growing penetration of mobile technology in healthcare industry 102
?
5.2.5 CHALLENGES 102
5.2.5.1 Evolving regulatory landscape and compliance requirements 102
5.2.5.2 Concerns regarding data security & privacy 103
5.2.5.3 Lack of interoperability & integration 104
5.2.5.4 Resistance from traditional healthcare professionals and concerns regarding software reliability 104
6 INDUSTRY INSIGHTS 106
6.1 INTRODUCTION 106
6.2 OVERVIEW OF KEY INDUSTRY TRENDS 106
6.2.1 RISING NUMBER OF DECENTRALIZED CLINICAL TRIALS 106
6.2.2 INCREASED FOCUS ON REAL-WORLD DATA (RWD) 107
6.3 VALUE/SUPPLY CHAIN ANALYSIS 108
FIGURE 27 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: VALUE CHAIN ANALYSIS (2023) 108
6.4 ECOSYSTEM ANALYSIS 109
FIGURE 28 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: ECOSYSTEM ANALYSIS (2023) 109
6.5 TECHNOLOGY ANALYSIS 109
6.5.1 KEY TECHNOLOGIES 109
6.5.1.1 Machine learning 109
6.5.1.2 Artificial intelligence 110
6.5.1.3 Internet of things 110
6.5.1.4 Integrated APIs 110
6.5.2 COMPLEMENTARY TECHNOLOGIES 111
6.5.2.1 Interactive Voice Response (IVR) 111
6.5.2.2 Data analytics 111
6.5.2.3 Telehealth 111
6.5.3 ADJACENT TECHNOLOGIES 112
6.5.3.1 Cloud computing 112
6.5.3.2 Blockchain 112
6.6 REGULATORY LANDSCAPE 112
6.6.1 REGULATORY ANALYSIS 112
6.6.1.1 North America 112
6.6.1.2 Europe 114
6.6.1.3 Asia Pacific 114
6.6.1.4 Latin America 115
6.6.1.5 Middle East & Africa 115
6.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 116
TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 116
TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 116
TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 117
TABLE 10 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 117
6.7 PORTER'S FIVE FORCES ANALYSIS 118
TABLE 11 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: PORTER'S FIVE FORCES ANALYSIS 118
6.7.1 COMPETITIVE RIVALRY 119
6.7.2 BARGAINING POWER OF BUYERS 119
6.7.3 BARGAINING POWER OF SUPPLIERS 119
6.7.4 THREAT OF SUBSTITUTES 119
6.7.5 THREAT OF NEW ENTRANTS 119
6.8 PRICING ANALYSIS 120
6.8.1 AVERAGE SELLING PRICE TREND, BY REGION 121
6.8.2 INDICATIVE PRICING ANALYSIS, BY PRODUCT 121
TABLE 12 AVERAGE SELLING PRICE OF ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS, BY SOLUTION TYPE (2023) 121
6.9 CASE STUDY ANALYSIS 122
6.9.1 CASE 1: A LEADING ACADEMIC MEDICAL CENTER MONITORS NEWLY DIAGNOSED MYELOMA PATIENTS WITH MEDIDATA ECOA 122
6.9.2 CASE 2: SIGNANT'S SCALE MANAGEMENT EXPERTISE FACILITATES ENDPOINT ACCURACY & RELIABILITY IN PSORIATIC ARTHRITIS TRIAL 123
6.10 PATENT ANALYSIS 124
FIGURE 29 TOP PATENT OWNERS AND APPLICANTS FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS (JANUARY 2011-JANUARY 2024) 125
FIGURE 30 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: PATENT ANALYSIS (JANUARY 2011-JANUARY 2024) 126
FIGURE 31 TOP APPLICANT COUNTRIES/REGIONS FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTION PATENTS (JANUARY 2011-JANUARY 2024) 126
TABLE 13 LIST OF PATENTS/PATENT APPLICATIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, 2021-2023 127
6.11 KEY CONFERENCES & EVENTS, 2023-2024 128
TABLE 14 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: DETAILED LIST OF CONFERENCES & EVENTS 128
6.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES 129
FIGURE 32 REVENUE SHIFT IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET 129
6.13 KEY STAKEHOLDERS & BUYING CRITERIA 130
6.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 130
FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 END USERS 130
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS 130
6.13.2 BUYING CRITERIA 131
FIGURE 34 KEY BUYING CRITERIA FOR END USERS 131
TABLE 16 KEY BUYING CRITERIA FOR END USERS 131
6.14 END-USER ANALYSIS 131
6.14.1 UNMET NEEDS 131
TABLE 17 UNMET NEEDS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET 132
6.14.2 END-USER EXPECTATIONS 133
TABLE 18 END-USER EXPECTATIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET 133
6.15 REVENUE MODEL ANALYSIS 133
6.15.1 SUBSCRIPTION-BASED MODEL 133
6.15.2 PAY-PER-STUDY MODEL 134
6.15.3 CUSTOMIZED SOLUTIONS MODEL 134
6.15.4 SOFTWARE-AS-A-SERVICE (SAAS) MODEL 134
6.15.5 CONSULTING AND INTEGRATION SERVICES MODEL 134
6.16 INVESTMENT LANDSCAPE 135
FIGURE 35 RECENT INVESTMENTS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET 135
7 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT 136
7.1 INTRODUCTION 137
TABLE 19 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION) 137
TABLE 20 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION) 137
7.2 SOFTWARE 138
7.2.1 ADVANTAGES OF ECOA SOFTWARE LIKE REAL-TIME ANALYSIS AND STREAMLINED DATA COLLECTION TO FOSTER MARKET GROWTH 138
TABLE 21 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR SOFTWARE, BY COUNTRY, 2018-2022 (USD MILLION) 139
TABLE 22 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR SOFTWARE, BY COUNTRY, 2023-2029 (USD MILLION) 140
7.3 SERVICES 140
7.3.1 ABILITY OF ECOA SERVICES TO REDUCE TIME AND COST OF CLINICAL TRIAL PROCESSES TO BOOST DEMAND 140
TABLE 23 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR SERVICES, BY COUNTRY, 2018-2022 (USD MILLION) 141
TABLE 24 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR SERVICES, BY COUNTRY, 2023-2029 (USD MILLION) 142
7.4 WEARABLES, MOBILE DEVICES, AND OTHER DEVICES 142
TABLE 25 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION) 143
TABLE 26 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION) 143
TABLE 27 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY COUNTRY, 2018-2022 (USD MILLION) 144
TABLE 28 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY COUNTRY, 2023-2029 (USD MILLION) 145
7.4.1 BRING YOUR OWN DEVICE (BYOD) MODEL 145
7.4.1.1 Ability of BYOD models to increase flexibility and convenience to drive adoption 145
TABLE 29 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR BRING YOUR OWN DEVICE (BYOD) MODELS, BY COUNTRY, 2018-2022 (USD MILLION) 146
TABLE 30 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR BRING YOUR OWN DEVICE (BYOD) MODELS, BY COUNTRY, 2023-2029 (USD MILLION) 147
7.4.2 PROVISIONED DEVICE MODEL 147
7.4.2.1 Growing need for standardization and control in data collection process to support market growth 147
TABLE 31 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR PROVISIONED DEVICE MODELS, BY COUNTRY, 2018-2022 (USD MILLION) 148
TABLE 32 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR PROVISIONED DEVICE MODELS, BY COUNTRY, 2023-2029 (USD MILLION) 149
7.4.3 HYBRID MODEL 149
7.4.3.1 Ability of hybrid models to increase balance between standardization and participant preferences to favor growth 149
TABLE 33 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR HYBRID MODELS, BY COUNTRY, 2018-2022 (USD MILLION) 150
TABLE 34 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR HYBRID MODELS, BY COUNTRY, 2023-2029 (USD MILLION) 151
8 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT 152
8.1 INTRODUCTION 153
TABLE 35 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION) 153
TABLE 36 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION) 154
8.2 ELECTRONIC PATIENT-REPORTED OUTCOMES (EPRO) 154
8.2.1 GROWING EMPHASIS ON PATIENT-CENTRIC HEALTHCARE TO BOOST MARKET GROWTH 154
TABLE 37 ELECTRONIC PATIENT-REPORTED OUTCOMES (EPRO) MARKET, BY COUNTRY, 2018-2022 (USD MILLION) 155
TABLE 38 ELECTRONIC PATIENT-REPORTED OUTCOMES (EPRO) MARKET, BY COUNTRY, 2023-2029 (USD MILLION) 156
8.3 ELECTRONIC OBSERVER-REPORTED OUTCOMES (EOBSRO) 156
8.3.1 GROWING NEED FOR ACCURATE AND RELIABLE DATA COLLECTION TO DRIVE ADOPTION OF EOBSRO SOLUTIONS 156
TABLE 39 ELECTRONIC OBSERVER-REPORTED OUTCOMES (EOBSRO) MARKET, BY COUNTRY, 2018-2022 (USD MILLION) 157
TABLE 40 ELECTRONIC OBSERVER-REPORTED OUTCOMES (EOBSRO) MARKET, BY COUNTRY, 2023-2029 (USD MILLION) 158
8.4 ELECTRONIC CLINICIAN-REPORTED OUTCOMES (ECLINRO) 158
8.4.1 INCREASING EFFICACY AND ACCURACY IN CAPTURING CLINICIAN-REPORTED DATA TO PROPEL GROWTH 158
TABLE 41 ELECTRONIC CLINICIAN-REPORTED OUTCOMES (ECLINRO) MARKET, BY COUNTRY, 2018-2022 (USD MILLION) 159
TABLE 42 ELECTRONIC CLINICIAN-REPORTED OUTCOMES (ECLINRO) MARKET, BY COUNTRY, 2023-2029 (USD MILLION) 160
8.5 ELECTRONIC PERFORMANCE-REPORTED OUTCOME (EPERFO) 160
8.5.1 INCREASING ACCESSIBILITY AND FLEXIBILITY IN CLINICAL TRIAL SETTINGS TO BOOST MARKET 160
TABLE 43 ELECTRONIC PERFORMANCE-REPORTED OUTCOMES (EPERFO) MARKET, BY COUNTRY, 2018-2022 (USD MILLION) 161
TABLE 44 ELECTRONIC PERFORMANCE-REPORTED OUTCOMES (EPERFO) MARKET, BY COUNTRY, 2023-2029 (USD MILLION) 162
9 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL 163
9.1 INTRODUCTION 164
TABLE 45 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION) 164
TABLE 46 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION) 164
9.2 ON-PREMISE MODEL 164
9.2.1 OPTIMAL CONTROL ON DEPLOYMENT AND DATA BACKUP TO SUPPORT MARKET UPTAKE 164
TABLE 47 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR ON-PREMISE MODELS, BY REGION, 2018-2022 (USD MILLION) 165
TABLE 48 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR ON-PREMISE MODELS, BY REGION, 2023-2029 (USD MILLION) 166
9.3 WEB-HOSTED & CLOUD-BASED MODEL 166
9.3.1 ENHANCED QUALITY OF CLINICAL TRIALS WITH IMPROVED PRODUCTIVITY TO DRIVE MARKET 166
TABLE 49 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEB-HOSTED & CLOUD-BASED MODELS, BY REGION, 2018-2022 (USD MILLION) 167
TABLE 50 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEB-HOSTED & CLOUD-BASED MODELS, BY REGION, 2023-2029 (USD MILLION) 168
9.4 HYBRID MODEL 168
9.4.1 ABILITY TO OFFER BALANCED SOLUTIONS USING HYBRID MODEL TO SUPPORT MARKET GROWTH 168
TABLE 51 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR HYBRID MODELS, BY REGION, 2018-2022 (USD MILLION) 169
TABLE 52 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR HYBRID MODELS, BY REGION, 2023-2029 (USD MILLION) 170
10 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION 171
10.1 INTRODUCTION 172
TABLE 53 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION) 172
TABLE 54 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION) 172
10.2 CLINICAL TRIALS 173
TABLE 55 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION) 173
TABLE 56 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY THERAPEUTIC AREAS, 2023-2029 (USD MILLION) 174
TABLE 57 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2018-2022 (USD MILLION) 174
TABLE 58 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2023-2029 (USD MILLION) 175
10.2.1 ONCOLOGY 176
10.2.1.1 Rising incidence of cancer to drive market growth 176
FIGURE 36 US: CANCER INCIDENCE IN MALES, BY TYPE (2022) 176
FIGURE 37 US: CANCER INCIDENCE IN FEMALES, BY TYPE (2022) 176
FIGURE 38 GLOBAL ONCOLOGY CLINICAL TRIALS, 2010-2021 (THOUSAND) 177
TABLE 59 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR ONCOLOGY, BY COUNTRY, 2018-2022 (USD MILLION) 178
TABLE 60 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2029 (USD MILLION) 179
10.2.2 INFECTIOUS DISEASES 179
10.2.2.1 Growing focus on infectious disease treatment and management to boost market 179
TABLE 61 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2018-2022 (USD MILLION) 180
TABLE 62 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023-2029 (USD MILLION) 181
10.2.3 NEUROLOGY 181
10.2.3.1 Increasing investments in R&D and grants for neurological disorders to drive market 181
TABLE 63 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR NEUROLOGY, BY COUNTRY, 2018-2022 (USD MILLION) 182
TABLE 64 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR NEUROLOGY, BY COUNTRY, 2023-2029 (USD MILLION) 183
10.2.4 METABOLIC DISORDERS 183
10.2.4.1 Rising diabetes incidence to drive market 183
FIGURE 39 INCREASE IN DIABETES CASES, 2000-2045 (MILLION INDIVIDUALS) 184
TABLE 65 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2018-2022 (USD MILLION) 184
TABLE 66 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2023-2029 (USD MILLION) 185
10.2.5 IMMUNOLOGY 185
10.2.5.1 Increasing development of immunology drugs to drive demand for eCOA solutions 185
TABLE 67 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2018-2022 (USD MILLION) 186
TABLE 68 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023-2029 (USD MILLION) 187
10.2.6 CARDIOVASCULAR DISEASES 187
10.2.6.1 Need for efficient and reliable means of collecting patient-reported outcomes in cardiovascular trials to support growth 187
TABLE 69 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2022 (USD MILLION) 188
TABLE 70 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2029 (USD MILLION) 189
10.2.7 RARE DISEASES & GENETIC DISORDERS 189
10.2.7.1 Growing government support for rare diseases & genetic disorders to boost market 189
TABLE 71 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR RARE DISEASES & GENETIC DISORDERS, BY COUNTRY, 2018-2022 (USD MILLION) 190
TABLE 72 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR RARE DISEASES & GENETIC DISORDERS, BY COUNTRY, 2023-2029 (USD MILLION) 191
10.2.8 MENTAL HEALTH DISORDERS 191
10.2.8.1 Growing awareness of mental health disorders to contribute to market growth 191
TABLE 73 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR MENTAL HEALTH DISORDERS, BY COUNTRY, 2018-2022 (USD MILLION) 192
TABLE 74 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR MENTAL HEALTH DISORDERS, BY COUNTRY, 2023-2029 (USD MILLION) 193
10.2.9 OTHER THERAPEUTIC AREAS 193
TABLE 75 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2018-2022 (USD MILLION) 194
TABLE 76 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2029 (USD MILLION) 195
10.3 OBSERVATIONAL STUDIES & REAL-WORLD EVIDENCE (RWE) GENERATION 195
10.3.1 GROWING RECOGNITION OF BENEFITS OF REAL-WORLD EVIDENCE GENERATION TO DRIVE DEMAND 195
TABLE 77 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OBSERVATIONAL STUDIES & REAL-WORLD EVIDENCE (RWE) GENERATION, BY COUNTRY, 2018-2022 (USD MILLION) 196
TABLE 78 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OBSERVATIONAL STUDIES & REAL-WORLD EVIDENCE (RWE) GENERATION, BY COUNTRY, 2023-2029 (USD MILLION) 197
?
10.4 PATIENT MANAGEMENT & REGISTRIES 197
10.4.1 EVOLVING LANDSCAPE OF PATIENT-CENTRIC HEALTHCARE TO DRIVE SEGMENTAL GROWTH 197
TABLE 79 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR PATIENT MANAGEMENT & REGISTRIES, BY COUNTRY, 2018-2022 (USD MILLION) 198
TABLE 80 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR PATIENT MANAGEMENT & REGISTRIES, BY COUNTRY, 2023-2029 (USD MILLION) 199
10.5 OTHER APPLICATIONS 199
TABLE 81 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2018-2022 (USD MILLION) 200
TABLE 82 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023-2029 (USD MILLION) 201
11 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER 202
11.1 INTRODUCTION 203
TABLE 83 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION) 203
TABLE 84 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION) 204
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 204
11.2.1 INCREASING R&D EXPENDITURE FOR DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET 204
TABLE 85 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2022 (USD MILLION) 205
TABLE 86 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2029 (USD MILLION) 206
11.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) 206
11.3.1 RISING OUTSOURCING OF CLINICAL TRIAL ACTIVITIES TO CROS BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET 206
TABLE 87 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2018-2022 (USD MILLION) 207
TABLE 88 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023-2029 (USD MILLION) 208
11.4 GOVERNMENT ORGANIZATIONS 208
11.4.1 GROWING COLLABORATIONS BETWEEN GOVERNMENT ORGANIZATIONS AND CROS TO PROPEL GROWTH 208
TABLE 89 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR GOVERNMENT ORGANIZATIONS, BY COUNTRY, 2018-2022 (USD MILLION) 209
TABLE 90 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR GOVERNMENT ORGANIZATIONS, BY COUNTRY, 2023-2029 (USD MILLION) 210
11.5 MEDTECH COMPANIES 210
11.5.1 GROWING UTILIZATION OF CLINICAL DATA SOFTWARE SOLUTIONS FOR MEDICAL DEVICE TRIALS TO FUEL GROWTH 210
TABLE 91 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR MEDTECH COMPANIES, BY COUNTRY, 2018-2022 (USD MILLION) 211
TABLE 92 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR MEDTECH COMPANIES, BY COUNTRY, 2023-2029 (USD MILLION) 212
11.6 HOSPITALS & HEALTHCARE PROVIDERS 212
11.6.1 INCREASING IT BUDGETS TO STREAMLINE PATIENT DATABASES TO PROPEL MARKET GROWTH 212
TABLE 93 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR HOSPITALS & HEALTHCARE PROVIDERS, BY COUNTRY, 2018-2022 (USD MILLION) 213
TABLE 94 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR HOSPITALS & HEALTHCARE PROVIDERS, BY COUNTRY, 2023-2029 (USD MILLION) 214
11.7 ACADEMIC & RESEARCH INSTITUTES 214
11.7.1 FAVORABLE GOVERNMENT SUPPORT FOR CLINICAL RESEARCH TO SUPPORT MARKET GROWTH 214
TABLE 95 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2022 (USD MILLION) 215
TABLE 96 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2029 (USD MILLION) 216
11.8 CONSULTING SERVICE COMPANIES 216
11.8.1 GROWING COLLABORATIONS BETWEEN CONSULTANCY FIRMS AND PHARMA & BIOTECH COMPANIES TO DRIVE MARKET 216
TABLE 97 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CONSULTING SERVICE COMPANIES, BY COUNTRY, 2018-2022 (USD MILLION) 217
TABLE 98 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CONSULTING SERVICE COMPANIES, BY COUNTRY, 2023-2029 (USD MILLION) 218
12 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY REGION 219
12.1 INTRODUCTION 220
TABLE 99 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY REGION, 2018-2022 (USD MILLION) 220
TABLE 100 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY REGION, 2023-2029 (USD MILLION) 220
12.2 NORTH AMERICA 221
FIGURE 40 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET SNAPSHOT 222
TABLE 101 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COUNTRY, 2018-2022 (USD MILLION) 223
TABLE 102 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COUNTRY, 2023-2029 (USD MILLION) 223
TABLE 103 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION) 223
TABLE 104 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION) 224
TABLE 105 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION) 224
TABLE 106 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION) 224
TABLE 107 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION) 225
TABLE 108 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION) 225
TABLE 109 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION) 226
TABLE 110 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION) 226
TABLE 111 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION) 226
TABLE 112 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION) 227
TABLE 113 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION) 227
TABLE 114 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION) 228
TABLE 115 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION) 228
TABLE 116 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION) 229
12.2.1 NORTH AMERICA: RECESSION IMPACT 229
12.2.2 US 230
12.2.2.1 Rising government funding for pharmaceutical R&D to drive market 230
FIGURE 41 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2021 VS. 2022) 230
TABLE 117 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION) 231
TABLE 118 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION) 231
TABLE 119 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION) 232
TABLE 120 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION) 232
TABLE 121 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION) 233
TABLE 122 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION) 233
TABLE 123 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION) 234
TABLE 124 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION) 234
TABLE 125 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION) 234
TABLE 126 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION) 235
TABLE 127 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION) 235
TABLE 128 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION) 236
TABLE 129 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION) 236
TABLE 130 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION) 237
12.2.3 CANADA 237
12.2.3.1 Increasing number of clinical trials to support market growth 237
TABLE 131 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION) 238
TABLE 132 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION) 238
TABLE 133 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION) 238
TABLE 134 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION) 239
TABLE 135 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION) 239
TABLE 136 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION) 240
TABLE 137 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION) 240
TABLE 138 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION) 241
TABLE 139 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION) 241
TABLE 140 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION) 242
TABLE 141 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION) 242
TABLE 142 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION) 243
TABLE 143 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION) 243
TABLE 144 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION) 244

12.3 EUROPE 244
TABLE 145 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COUNTRY, 2018-2022 (USD MILLION) 245
TABLE 146 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COUNTRY, 2023-2029 (USD MILLION) 245
TABLE 147 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION) 246
TABLE 148 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION) 246
TABLE 149 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION) 246
TABLE 150 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION) 247
TABLE 151 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION) 247
TABLE 152 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION) 248
TABLE 153 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION) 248
TABLE 154 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION) 249
TABLE 155 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION) 249
TABLE 156 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION) 250
TABLE 157 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION) 250
TABLE 158 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION) 251
TABLE 159 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION) 251
TABLE 160 EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION) 252
12.3.1 EUROPE: RECESSION IMPACT 252
12.3.2 GERMANY 253
12.3.2.1 Increase in R&D expenditure and clinical trials to boost market growth 253
TABLE 161 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION) 253
TABLE 162 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION) 254
TABLE 163 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION) 254
TABLE 164 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION) 254
TABLE 165 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION) 255
TABLE 166 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION) 255
TABLE 167 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION) 256
TABLE 168 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION) 256
TABLE 169 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION) 256
TABLE 170 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION) 257
TABLE 171 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION) 257
TABLE 172 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION) 258
TABLE 173 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION) 258
TABLE 174 GERMANY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION) 259
12.3.3 UK 259
12.3.3.1 Growing investments in drug discovery services to favor market growth 259
TABLE 175 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION) 260
TABLE 176 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION) 260
TABLE 177 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION) 261
TABLE 178 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION) 261
TABLE 179 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION) 262
TABLE 180 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION) 262
TABLE 181 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION) 263
TABLE 182 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION) 263
TABLE 183 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION) 263
TABLE 184 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION) 264
TABLE 185 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION) 264
TABLE 186 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION) 265
TABLE 187 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION) 265
TABLE 188 UK: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION) 266
12.3.4 FRANCE 266
12.3.4.1 Growing R&D pipeline for oncology trials to drive market 266
TABLE 189 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION) 267
TABLE 190 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION) 267
TABLE 191 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION) 268
TABLE 192 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION) 268
TABLE 193 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION) 269
TABLE 194 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION) 269
TABLE 195 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION) 270
TABLE 196 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION) 270
TABLE 197 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION) 270
TABLE 198 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION) 271
TABLE 199 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION) 271
TABLE 200 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION) 272
TABLE 201 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION) 272
TABLE 202 FRANCE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION) 273
12.3.5 ITALY 273
12.3.5.1 Increasing government funds and favorable regulatory scenarios to fuel uptake 273
TABLE 203 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION) 274
TABLE 204 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION) 274
TABLE 205 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION) 274
TABLE 206 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION) 275
TABLE 207 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION) 275
TABLE 208 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION) 276
TABLE 209 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION) 276
TABLE 210 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION) 277
TABLE 211 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION) 277
TABLE 212 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION) 278
TABLE 213 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION) 278
TABLE 214 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION) 279
TABLE 215 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION) 279
TABLE 216 ITALY: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION) 280
12.3.6 REST OF EUROPE 280
TABLE 217 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION) 281
TABLE 218 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION) 281
TABLE 219 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION) 282
TABLE 220 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION) 282
TABLE 221 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION) 283
TABLE 222 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION) 283
TABLE 223 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION) 284
TABLE 224 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION) 284
TABLE 225 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION) 284
TABLE 226 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION) 285
TABLE 227 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION) 285
TABLE 228 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION) 286
TABLE 229 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION) 286
TABLE 230 REST OF EUROPE: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION) 287
12.4 ASIA PACIFIC 287
FIGURE 42 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET SNAPSHOT 289
TABLE 231 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COUNTRY, 2018-2022 (USD MILLION) 290
TABLE 232 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COUNTRY, 2023-2029 (USD MILLION) 290
TABLE 233 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION) 290
TABLE 234 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION) 291
TABLE 235 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION) 291
TABLE 236 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION) 291
TABLE 237 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION) 292
TABLE 238 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION) 292
TABLE 239 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION) 293
TABLE 240 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION) 293
TABLE 241 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION) 293
TABLE 242 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION) 294
TABLE 243 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION) 294
TABLE 244 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION) 295
TABLE 245 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION) 295
TABLE 246 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION) 296
12.4.1 ASIA PACIFIC: RECESSION IMPACT 296
12.4.2 JAPAN 297
12.4.2.1 Established clinical trial infrastructure and increase in funds for R&D to support growth 297
TABLE 247 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION) 297
TABLE 248 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION) 298
TABLE 249 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION) 298
TABLE 250 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION) 298
TABLE 251 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION) 299
TABLE 252 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION) 299
TABLE 253 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION) 300
TABLE 254 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION) 300
TABLE 255 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION) 300
TABLE 256 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION) 301
TABLE 257 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION) 301
TABLE 258 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION) 302
TABLE 259 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION) 302
TABLE 260 JAPAN: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION) 303
12.4.3 CHINA 303
12.4.3.1 Low cost of clinical trials and large pharmaceutical R&D base to drive market 303
TABLE 261 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION) 304
TABLE 262 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION) 304
TABLE 263 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION) 305
TABLE 264 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION) 305
TABLE 265 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION) 306
TABLE 266 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION) 306
TABLE 267 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION) 307
TABLE 268 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION) 307
TABLE 269 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION) 307
TABLE 270 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION) 308
TABLE 271 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION) 308
TABLE 272 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION) 309
TABLE 273 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION) 309
TABLE 274 CHINA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION) 310
12.4.4 INDIA 310
12.4.4.1 Growing pharmaceutical industry to fuel uptake of eCOA solutions 310
TABLE 275 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION) 311
TABLE 276 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION) 311
TABLE 277 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION) 312
TABLE 278 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION) 312
TABLE 279 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION) 313
TABLE 280 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION) 313
TABLE 281 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION) 314
TABLE 282 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION) 314
TABLE 283 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION) 314
TABLE 284 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION) 315
TABLE 285 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION) 315
TABLE 286 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION) 316
TABLE 287 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION) 316
TABLE 288 INDIA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION) 317
12.4.5 REST OF ASIA PACIFIC 317
TABLE 289 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION) 318
TABLE 290 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION) 318
TABLE 291 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION) 318
TABLE 292 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION) 319
TABLE 293 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION) 319
TABLE 294 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION) 320
TABLE 295 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION) 320
TABLE 296 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION) 321
TABLE 297 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION) 321
TABLE 298 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION) 322
TABLE 299 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION) 322
TABLE 300 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION) 323
TABLE 301 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION) 323
TABLE 302 REST OF ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION) 324

12.5 LATIN AMERICA 324
12.5.1 LARGE POOL OF PHARMACEUTICAL COMPANIES TO FAVOR MARKET GROWTH 324
TABLE 303 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION) 325
TABLE 304 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION) 325
TABLE 305 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION) 326
TABLE 306 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION) 326
TABLE 307 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION) 327
TABLE 308 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION) 327
TABLE 309 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION) 328
TABLE 310 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION) 328
TABLE 311 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION) 328
TABLE 312 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION) 329
TABLE 313 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION) 329
TABLE 314 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION) 330
TABLE 315 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION) 330
TABLE 316 LATIN AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION) 331
12.5.2 LATIN AMERICA: RECESSION IMPACT 331
12.6 MIDDLE EAST & AFRICA 332
TABLE 317 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY REGION, 2018-2022 (USD MILLION) 332
TABLE 318 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY REGION, 2023-2029 (USD MILLION) 332
TABLE 319 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION) 333
TABLE 320 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION) 333
TABLE 321 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION) 333
TABLE 322 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION) 334
TABLE 323 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION) 334
TABLE 324 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION) 335
TABLE 325 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION) 335
TABLE 326 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION) 336
TABLE 327 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION) 336
TABLE 328 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION) 337
TABLE 329 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION) 337
TABLE 330 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION) 338
TABLE 331 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION) 338
TABLE 332 MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION) 339
12.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT 339
12.6.2 GCC COUNTRIES 340
12.6.2.1 Increase in healthcare investments to support market growth 340
TABLE 333 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION) 341
TABLE 334 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION) 341
TABLE 335 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION) 341
TABLE 336 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION) 342
TABLE 337 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION) 342
TABLE 338 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION) 343
TABLE 339 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION) 343
TABLE 340 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION) 344
TABLE 341 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION) 344
TABLE 342 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION) 345
TABLE 343 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION) 345
TABLE 344 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION) 346
TABLE 345 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION) 346
TABLE 346 GCC COUNTRIES: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION) 347
12.6.3 REST OF MIDDLE EAST & AFRICA 347
TABLE 347 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018-2022 (USD MILLION) 348
TABLE 348 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023-2029 (USD MILLION) 348
TABLE 349 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018-2022 (USD MILLION) 349
TABLE 350 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023-2029 (USD MILLION) 349
TABLE 351 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018-2022 (USD MILLION) 350
TABLE 352 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023-2029 (USD MILLION) 350
TABLE 353 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018-2022 (USD MILLION) 351
TABLE 354 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023-2029 (USD MILLION) 351
TABLE 355 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018-2022 (USD MILLION) 351
TABLE 356 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023-2029 (USD MILLION) 352
TABLE 357 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018-2022 (USD MILLION) 352
TABLE 358 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023-2029 (USD MILLION) 353
TABLE 359 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018-2022 (USD MILLION) 353
TABLE 360 REST OF MIDDLE EAST & AFRICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023-2029 (USD MILLION) 354
?
13 COMPETITIVE LANDSCAPE 355
13.1 OVERVIEW 355
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 355
TABLE 361 OVERVIEW OF STRATEGIES DEPLOYED BY KEY ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET VENDORS 356
13.3 REVENUE ANALYSIS 357
FIGURE 43 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: REVENUE ANALYSIS OF KEY PLAYERS (2018-2022) 358
13.4 MARKET SHARE ANALYSIS 358
FIGURE 44 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: MARKET SHARE ANALYSIS (2023) 358
TABLE 362 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: DEGREE OF COMPETITION 359
13.5 BRAND/SOFTWARE COMPARATIVE ANALYSIS 360
13.5.1 MEDIDATA (US) 360
13.5.2 IQVIA (US) 361
13.5.3 ICON PLC (IRELAND) 361
13.5.4 SIGNANT HEALTH (US) 361
13.5.5 CLARIO (US) 361
13.6 VALUATION AND FINANCIAL METRICS OF ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS VENDORS 362
FIGURE 45 EV/EBITDA OF KEY VENDORS 362
FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 362
13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS 363
13.7.1 STARS 363
13.7.2 EMERGING LEADERS 363
13.7.3 PERVASIVE PLAYERS 363
13.7.4 PARTICIPANTS 363
FIGURE 47 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 364
13.7.5 COMPANY FOOTPRINT ANALYSIS 365
FIGURE 48 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: COMPANY FOOTPRINT 365
TABLE 363 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: COMPONENT FOOTPRINT 366
TABLE 364 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: DEPLOYMENT MODEL FOOTPRINT 367
TABLE 365 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: END-USER FOOTPRINT 368
TABLE 366 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: REGIONAL FOOTPRINT 369
13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES 370
13.8.1 PROGRESSIVE COMPANIES 370
13.8.2 DYNAMIC COMPANIES 370
13.8.3 RESPONSIVE COMPANIES 370
13.8.4 STARTING BLOCKS 370
FIGURE 49 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 371
13.8.5 COMPETITIVE BENCHMARKING 372
TABLE 367 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) MARKET: DETAILED LIST OF KEY SMES/STARTUPS 372
TABLE 368 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (STARTUPS/SMES) 373
13.9 COMPETITIVE SCENARIO 374
TABLE 369 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: PRODUCT LAUNCHES & UPGRADES, JANUARY 2021-NOVEMBER 2023 374
TABLE 370 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET: DEALS, JANUARY 2021-NOVEMBER 2023 375
14 COMPANY PROFILES 376
(Business overview, Products/Services/Solutions offered, Recent Developments, MNM view)*
14.1 KEY PLAYERS 376
14.1.1 MEDIDATA (A DASSAULT SYSTEMES COMPANY) 376
TABLE 371 MEDIDATA: COMPANY OVERVIEW 376
FIGURE 50 DASSAULT SYSTEMES: COMPANY SNAPSHOT (2022) 377
TABLE 372 MEDIDATA: PRODUCTS/SOLUTIONS/SERVICES OFFERED 377
TABLE 373 MEDIDATA: PRODUCT/SERVICE LAUNCHES 378
TABLE 374 MEDIDATA: DEALS 378
14.1.2 IQVIA 380
TABLE 375 IQVIA: COMPANY OVERVIEW 380
FIGURE 51 IQVIA: COMPANY SNAPSHOT (2022) 381
TABLE 376 IQVIA: PRODUCTS/SOLUTIONS/SERVICES OFFERED 381
14.1.3 SIGNANT HEALTH 383
TABLE 377 SIGNANT HEALTH: COMPANY OVERVIEW 383
TABLE 378 SIGNANT HEALTH: PRODUCTS/SOLUTIONS/SERVICES OFFERED 383
TABLE 379 SIGNANT HEALTH: PRODUCT/SERVICE LAUNCHES & UPGRADES 384
TABLE 380 SIGNANT HEALTH: DEALS 384
14.1.4 CLARIO 386
TABLE 381 CLARIO: COMPANY OVERVIEW 386
TABLE 382 CLARIO: PRODUCTS/SOLUTIONS/SERVICES OFFERED 386
TABLE 383 CLARIO: DEALS 387
14.1.5 ICON PLC 389
TABLE 384 ICON PLC: COMPANY OVERVIEW 389
FIGURE 52 ICON PLC: COMPANY SNAPSHOT (2022) 390
TABLE 385 ICON PLC: PRODUCTS/SOLUTIONS/SERVICES OFFERED 390
TABLE 386 ICON PLC: PRODUCT/SERVICE LAUNCHES 391
TABLE 387 ICON PLC: DEALS 391
14.1.6 ORACLE CORPORATION 393
TABLE 388 ORACLE CORPORATION: COMPANY OVERVIEW 393
FIGURE 53 ORACLE CORPORATION: COMPANY SNAPSHOT (2022) 394
TABLE 389 ORACLE CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED 394
TABLE 390 ORACLE CORPORATION: DEALS 395
14.1.7 MEDABLE INC. 396
TABLE 391 MEDABLE INC.: COMPANY OVERVIEW 396
TABLE 392 MEDABLE INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 396
TABLE 393 MEDABLE INC.: PRODUCT/SERVICE LAUNCHES 396
TABLE 394 MEDABLE INC.: DEALS 397
14.1.8 MERATIVE L.P. 398
TABLE 395 MERATIVE L.P.: COMPANY OVERVIEW 398
TABLE 396 MERATIVE L.P.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 398
14.1.9 PAREXEL INTERNATIONAL (MA) CORPORATION 399
TABLE 397 PAREXEL INTERNATIONAL (MA) CORPORATION: COMPANY OVERVIEW 399
TABLE 398 PAREXEL INTERNATIONAL (MA) CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED 399
TABLE 399 PARAXEL INTERNATIONAL (MA) CORPORATION: EXPANSIONS 400
14.1.10 CLIMEDO HEALTH GMBH 401
TABLE 400 CLIMEDO HEALTH GMBH: COMPANY OVERVIEW 401
TABLE 401 CLIMEDO HEALTH GMBH: PRODUCTS/SOLUTIONS/SERVICES OFFERED 401
TABLE 402 CLIMEDO HEALTH GMBH: OTHER DEVELOPMENTS 401
14.1.11 HEALTHENTIA (A PRODUCT OF INNOVATION SPRINT) 402
TABLE 403 INNOVATION SPRINT: COMPANY OVERVIEW 402
TABLE 404 HEALTHENTIA: PRODUCTS/SOLUTIONS/SERVICES OFFERED 402
14.1.12 VEEVA SYSTEMS 403
TABLE 405 VEEVA SYSTEMS: COMPANY OVERVIEW 403
FIGURE 54 VEEVA SYSTEMS: COMPANY SNAPSHOT (2022) 404
TABLE 406 VEEVA SYSTEMS: PRODUCTS/SOLUTIONS/SERVICES OFFERED 404
TABLE 407 VEEVA SYSTEMS: PRODUCT/SERVICE LAUNCHES 405
TABLE 408 VEEVA SYSTEMS: DEALS 405
14.1.13 ASSISTEK 406
TABLE 409 ASSISTEK: COMPANY OVERVIEW 406
TABLE 410 ASSISTEK: PRODUCTS/SOLUTIONS/SERVICES OFFERED 406
TABLE 411 ASSISTEK: DEALS 407
14.1.14 CUREBASE INC. 408
TABLE 412 CUREBASE INC.: COMPANY OVERVIEW 408
TABLE 413 CUREBASE INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 408
TABLE 414 CUREBASE INC.: OTHER DEVELOPMENTS 408
14.1.15 CASTOR 409
TABLE 415 CASTOR: COMPANY OVERVIEW 409
TABLE 416 CASTOR: PRODUCTS/SOLUTIONS/SERVICES OFFERED 409
TABLE 417 CASTOR: PRODUCT/SERVICE LAUNCHES 410
TABLE 418 CASTOR: OTHER DEVELOPMENTS 410
14.1.16 EVIDENTIQ GROUP GMBH 411
TABLE 419 EVIDENTIQ GROUP GMBH: COMPANY OVERVIEW 411
TABLE 420 EVIDENTIQ GROUP GMBH: PRODUCTS/SOLUTIONS/SERVICES OFFERED 411
14.1.17 YPRIME, LLC 412
TABLE 421 YPRIME, LLC: COMPANY OVERVIEW 412
TABLE 422 YPRIME, LLC: PRODUCTS/SOLUTIONS/SERVICES OFFERED 412
TABLE 423 YPRIME, LLC: PRODUCT/SERVICE LAUNCHES 413
TABLE 424 YPRIME, LLC: DEALS 413
14.1.18 CLINICAL INK 414
TABLE 425 CLINICAL INK: COMPANY OVERVIEW 414
TABLE 426 CLINICAL INK: PRODUCTS/SOLUTIONS/SERVICES OFFERED 414
TABLE 427 CLINICAL INK: PRODUCT/SERVICE LAUNCHES & UPGRADES 415
TABLE 428 CLINICAL INK: DEALS 415
14.1.19 CLINION 416
TABLE 429 CLINION: COMPANY OVERVIEW 416
TABLE 430 CLINION: PRODUCTS/SOLUTIONS/SERVICES OFFERED 416
14.1.20 KAYENTIS 417
TABLE 431 KAYENTIS: COMPANY OVERVIEW 417
TABLE 432 KAYENTIS: PRODUCTS/SOLUTIONS/SERVICES OFFERED 417
TABLE 433 KAYENTIS: DEALS 418
TABLE 434 KAYENTIS: OTHER DEVELOPMENTS 418
14.2 OTHER PLAYERS 419
14.2.1 TRANSPERFECT 419
14.2.2 OBVIOHEALTH USA, INC. 419
14.2.3 WCG CLINICAL 420
14.2.4 ?LIN?APTURE 420
14.2.5 CLOUDBYZ 421
*Details on Business overview, Products/Services/Solutions offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
15 APPENDIX 422
15.1 DISCUSSION GUIDE 422
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL 429
15.3 CUSTOMIZATION OPTIONS 431
15.4 RELATED REPORTS 431
15.5 AUTHOR DETAILS 432

  • Not Sure / Need Reassuring
    • Confirm Content

      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages

      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives

      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices

      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts

      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies

      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses

      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License

      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats

      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery

      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges

      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card

      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer

      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security

      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security

      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE
  • $4950.00
  • $6650.00
  • $8150.00
  • $10000.00
  • ADD TO BASKET
  • BUY NOW

Related Reports

3D Bioprinting - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
 Market Report I 2025-04-28 I 100 Pages
Healthcare Cloud Computing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
 Market Report I 2025-04-28 I 120 Pages
US Biomedical Sensors - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
 Market Report I 2025-04-28 I 122 Pages

Don't forget we can help save time with your search, contact us and we'll prepare and send options

Healthcare Cyber Security - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
 Market Report I 2025-04-28 I 120 Pages
Latin America Medical Imaging Software - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
 Market Report I 2025-04-28 I 100 Pages